Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Arterial Thromboembolism in Cancer Patients Treated with Apixaban

Trine-Lise Larsen, Jorunn Brekke, Herish Garresori, Hege Frøen, Eva-Marie Jacobsen, Dag Torfoss, Hilde Skuterud Wik, Tone Ronnaug Enden, Alina Carmen Porojnicu, Petter Quist-Paulsen, Elin Velle, Per Morten Sandset, Anne Hansen Ree, Anders E.A. Dahm

Blood (2022) 140 (Supplement 1): 11366–11367.

https://doi.org/10.1182/blood-2022-160363

Published: 2022

Journal Articles

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Peter AW te Boekhorst, MD PhD, Alexandre Theocharides, MD, Heinz Gisslinger, MD, Timothy Devos, MD, Eric Lippert, MD PhD, Damianos Sotiropoulos, MD, Miklos Egyed, MD PhD, Valerio De Stefano, MD, Vincenzo Accurso, MD, Alessandra Iurlo, MD PhD, Anders E.A. Dahm, MD PhD, Regina Garcia-Delgado, MD, Nathan Cantoni, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erik Houtsma, MSc, Amir Iqbal, PhD, Paola Di Matteo, MD PhD, Alberto Alvarez-Larrán, MD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134210

Published: 2020

Journal Articles

Production of Tissue Factor Pathway Inhibitor in Endothelial Cell Cultures Is Reduced by Estrogens, Selective Estrogen Receptor Modifiers, and a Selective Estrogen Receptor Downregulator.

Anders E.A. Dahm, MD, Nina Iversen, PhD, Baard Birkenes, Per Morten Sandset, MD, PhD

Blood (2005) 106 (11): 3961.

https://doi.org/10.1182/blood.V106.11.3961.3961

Published: 2005

Journal Articles

Biological Relevance of a New TFPI Anticoagulant Activity Assay of Full-Length TFPI.

Anders E.A. Dahm, MD, Trine O. Andersen, Frits Rosendaal, MD, PhD, Per Morten Sandset, MD, PhD

Blood (2004) 104 (11): 2982.

https://doi.org/10.1182/blood.V104.11.2982.2982

Published: 2004

Journal Articles

A Novel Assay for Tissue Factor Pathway Inhibitor (TFPI) Anticoagulant Activity in Plasma.

Anders E.A. Dahm, MD, Trine O. Andersen, Frits Rosendaal, MD, PhD, Per Morten Sandset, MD, PhD

Blood (2004) 104 (11): 3987.

https://doi.org/10.1182/blood.V104.11.3987.3987

Published: 2004

NARROW

Arterial Thromboembolism in Cancer Patients Treated with Apixaban

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Production of Tissue Factor Pathway Inhibitor in Endothelial Cell Cultures Is Reduced by Estrogens, Selective Estrogen Receptor Modifiers, and a Selective Estrogen Receptor Downregulator.

Biological Relevance of a New TFPI Anticoagulant Activity Assay of Full-Length TFPI.

A Novel Assay for Tissue Factor Pathway Inhibitor (TFPI) Anticoagulant Activity in Plasma.

Email alerts

ASH Publications

American Society of Hematology

Arterial Thromboembolism in Cancer Patients Treated with Apixaban

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Production of Tissue Factor Pathway Inhibitor in Endothelial Cell Cultures Is Reduced by Estrogens, Selective Estrogen Receptor Modifiers, and a Selective Estrogen Receptor Downregulator.

Biological Relevance of a New TFPI Anticoagulant Activity Assay of Full-Length TFPI.

A Novel Assay for Tissue Factor Pathway Inhibitor (TFPI) Anticoagulant Activity in Plasma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only